Srs Capital Advisors, Inc. Entrada Therapeutics, Inc. Transaction History
Srs Capital Advisors, Inc.
- $977 Million
- Q2 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 45 shares of TRDA stock, worth $720. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45Holding current value
$720% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TRDA
# of Institutions
84Shares Held
27.7MCall Options Held
100Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$77.9 Million0.92% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$70.8 Million34.63% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$70.5 Million29.39% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.13MShares$50.2 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$27.1 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $502M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...